Rapt Therapeutics Inc.

The sponsor’s clinical research is centered on asthma, with a focus on adults living with T2-high asthma and persistent symptoms despite maintenance treatment. The funded study addresses partially controlled asthma and the need to improve control in patients receiving standard inhaled therapy.

• Moderate-to-severe asthma
• T2-high airway inflammation
• Loss of asthma control

Research activity in this area reflects interest in respiratory disease management, especially clinical outcomes related to symptom control and exacerbation risk in patients using inhaled corticosteroids and long-acting beta2 agonists.